level-one heading

Why Kolabtree
Getting started is quick and easy. No upfront fees
It’s free to request a service and invite bids from experts
Discuss requirements with the expert in detail before accepting statement of work from Kolabtree
Collaborate with the expert directly to get your work done the right way
Fund project when you hire the expert, but approve the deliverables only once work is done
Want to hire this expert for a project? Request a quote for free.
Profile Details
Create Project
★★★★★
☆☆☆☆☆
USD 130 /hr
Hire Dr. Petra D.
United Kingdom
USD 130 /hr

Science writer | Gene Therapy | Oligonucleotide Therapeutics | Social Media | DE-EN scientific translation

Profile Summary
Subject Matter Expertise
Services
Writing Copywriting, General Proofreading & Editing, Translation
Research Scientific and Technical Research, Systematic Literature Review
Consulting Digital Strategy Consulting, Scientific and Technical Consulting
Data & AI Statistical Analysis, Image Processing, Image Analysis, Data Visualization, Data Processing, Data Insights
Work Experience

Grant reviewer and panelist

Rosetree's Trust

November 2017 - Present

Hourly Paid Lecturer/Module Leader

Brunel University London, UK

September 2023 - July 2025

Medical / Science writer

Oligonucleotide Therapeutics Society

March 2016 - June 2021

Senior Post-doctoral Research Associate

University College London, UK

June 2015 - August 2017

Post-Doctoral Research Associate

University College London, UK

August 2014 - February 2015

Senior Post-doctoral Research Associate

University College London, UK

August 2012 - July 2014

Post-Doctoral Research Associate

University College London, UK

September 2009 - July 2012

Post-Doctoral Research Associate

Imperial College London, UK

October 2008 - August 2009

Graduate Research Assistant / Research Assistant

University of Oxford, Sir William Dunn School of Pathology

July 2001 - July 2004

Education

PhD in Gene Therapy

University College London, University of London - United Kingdom

September 2004 - October 2008

MSc

Julius-Maximilians-Universität of Würzburg

September 1997 - October 2000

Certifications
  • Certification details not provided.
Publications
JOURNAL ARTICLE
Godfrey, C., Desviat, L.R., Smedsrød, B., Piétri-Rouxel, F., Denti, M.A., Disterer, P., Lorain, S., Nogales-Gadea, G., Sardone, V., Anwar, R., et al.(2017). Delivery is key: Lessons learnt from developing splice-switching antisense therapies . EMBO Molecular Medicine.
Theodoraki, A., Hu, Y., Poopalasundaram, S., Oosterhof, A., Guimond, S.E., Disterer, P., Khoo, B., Hauge-Evans, A.C., Jones, P.M., Turnbull, J.E., et al.(2015). Distinct patterns of heparan sulphate in pancreatic islets suggest novel roles in paracrine islet regulation . Molecular and Cellular Endocrinology. 399. p. 296-310.
Disterer, P., Kryczka, A., Liu, Y., Badi, Y.E., Wong, J.J., Owen, J.S., Khoo, B.(2014). Development of therapeutic splice-switching oligonucleotides . Human Gene Therapy. 25. (7). p. 587-598.
Disterer, P., Al-Shawi, R., Ellmerich, S., Waddington, S.N., Owen, J.S., Simons, J.P., Khoo, B.(2013). Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol In Vivo . Molecular Therapy. 21. (3). p. 602-609.
Simons, J.P., Al-Shawi, R., Ellmerich, S., Speck, I., Aslam, S., Hutchinson, W.L., Mangione, P.P., Disterer, P., Gilbertson, J.A., Hunt, T., et al.(2013). Pathogenetic mechanisms of amyloid A amyloidosis . Proceedings of the National Academy of Sciences of the United States of America. 110. (40). p. 16115-16120.
Disterer, P., Papaioannou, I., Evans, V.C., Paul Simons, J., Owen, J.S.(2012). Oligonucleotide-mediated gene editing is underestimated in cells expressing mutated green fluorescent protein and is positively associated with target protein expression . Journal of Gene Medicine. 14. (2). p. 109-119.
Disterer, P., Simons, J.P., Owen, J.S.(2009). Validation of oligonucleotide-mediated gene editing . Gene Therapy. 16. (6). p. 824-826.
Baskakov, I., Disterer, P., Breydo, L., Shaw, M., Gill, A., James, W., Tahiri-Alaoui, A.(2005). The presence of valine at residue 129 in human prion protein accelerates amyloid formation . FEBS Letters. 579. (12). p. 2589-2596.
Tahiri-Alaoui, A., Gill, A.C., Disterer, P., James, W.(2004). Methionine 129 variant of human prion protein oligomerizes more rapidly than the valine 129 variant. Implications for disease susceptibility to Creutzfeldt-Jakob disease . Journal of Biological Chemistry. 279. (30). p. 31390-31397.
Rhie, A., Kirby, L., Sayer, N., Wellesley, R., Disterer, P., Sylvester, I., Gill, A., Hope, J., James, W., Tahiri-Alaoui, A.(2003). Characterization of 2′-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion . Journal of Biological Chemistry. 278. (41). p. 39697-39705.
Thiel, V., Karl, N., Schelle, B., Disterer, P., Klagge, I., Siddell, S.G.(2003). Multigene RNA vector based on coronavirus transcription . Journal of Virology. 77. (18). p. 9790-9798.
BOOK
Disterer, P., Khoo, B.(2012). Antisense-mediated exon-skipping to induce gene knockdown . Methods in Molecular Biology. 867. p. 289-305.
Disterer, P., Osman, E., Owen, J.S.(2008). Gene therapy for apolipoprotein A-I and HDL - The ultimate treatment for atherosclerosis . Vascular Complications in Human Disease: Mechanisms and Consequences. p. 197-212.